The effect of different sequences of vaccination against COVID and the fluon protection and safety
Phase 1
- Conditions
- Immunogenicity of the consecutive vaccination with both an mRNACOVID-19 vaccin and Influenza vaccin, in different sequencesTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2021-002186-17-NL
- Lead Sponsor
- RadboudUMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Age equal to or above 18 years
No previous COVID-vaccine
Healthy (=no chronic disease or medication use)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 160
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
History of COVID-19 infection, confirmed by a microbiological test
Vaccinated against influenza in the past 6 months
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method